6-K 1 http://www.sec.gov/Archives/edgar/data/1121404/000112140424000003/a6kcoverpagepressreleaseq4.htm 6-K Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 6-K
 
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2024

Commission File Number: 001-31368
 
 
SANOFI
(Translation of registrant’s name into English)
 
 
46, avenue de la Grande Armée, 75017 Paris, FRANCE
(Address of principal executive offices)


Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F  ☒            Form 40-F  ☐





In February 2024, Sanofi issued the press release attached hereto as Exhibit 99.1 which is incorporated herein by reference.


Exhibit Index


Exhibit No.
                                               Description
Exhibit 99.1
Press release dated February 1, 2024: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: February 1, 2024SANOFI
By:                              /s/ Alexandra Roger
Name:Alexandra Roger
Title:Head of Legal Corporate & Finance